An interventional study of EIT-Guided PEEP Titration Group and ARDSNet/PEEP-FiO₂ Table in Acute Respiratory Distress Syndrome (ARDS), sponsored by XIE MIN. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by XIE MIN · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Respiratory Distress Syndrome with a site in China — 54 open to participants now, 55 under way, 6 of them phase 3. Respiratory Distress Syndrome · China.
Among the 146 studies in Respiratory Distress Syndrome with a site in China, this one is the 58th largest by planned enrollment of the 81 interventional ones that give a count, is one of 14 that started in 2026, is one of 52 with no phase, reaches primary completion later than 37 of the 54 other live ones, and was the 143rd registered.
1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 282 are open to participants now.
Browse Respiratory Distress Syndrome studies →54 of the 146 studies in Respiratory Distress Syndrome with a site in China are open now. Recruiting first, the newest first:
Southeast University, China · Sites in China
Ruijin Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Bin Du · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 16 · Phase 3 7 · Phase 4 5
First in 2006; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 822 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 100 across the 81 interventional studies, 139 across the 65 observational. Of the 52 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 146 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with XIE MIN as lead sponsor.
XIE MIN has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
17 of the studies in Respiratory Distress Syndrome with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07342205Phase 3Shanghai University of Traditional Chinese MedicineA Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation | 2027-06 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07798154Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEffect of Spontaneous Breathing in APRV Mode on Respiratory Physiology of ARDS Patients | 2026-11 |
| NCT07413094Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | 2026-12 |
| NCT06430554Zhongda HospitalPersonalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability | 2026-12-30 |
Add all 17 to your calendar (.ics) → With an account.
Among the 146 studies in Respiratory Distress Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Electrical impedance tomography (EIT)-guided PEEP titration has been shown to improve regional ventilation distribution, increase respiratory system compliance, and reduce mechanical power in patients with acute respiratory distress syndrome (ARDS), but its effect on mortality remains unproven. In patients with moderate-to-severe ARDS, prone positioning for 4 hours allows pulmonary ventilation and perfusion to reach a new steady state, with optimization of ventilation-perfusion (V/Q) matching and other pulmonary physiological parameters. However, whether dynamic PEEP titration guided by EIT at this time point can further optimize V/Q matching and other pulmonary physiological parameters compared with conventional methods has not been reported.
Objective: To investigate whether EIT-guided PEEP titration performed at 4 hours after prone positioning initiation can further optimize V/Q matching and other pulmonary physiological parameters in patients with moderate-to-severe ARDS undergoing prone positioning.
Methods: This is a prospective, single-center, randomized, open-label, parallel-controlled physiological study. A total of 40 patients with moderate-to-severe ARDS (Berlin definition, PaO₂/FiO₂ \< 150 mmHg) will be enrolled and randomized in a 1:1 ratio to either the EIT-guided group or the control group. PEEP intervention will be performed at 4 hours after prone positioning initiation (T1) in both groups: the EIT group receives EIT-guided PEEP titration, while the control group receives PEEP set according to the ARDSNet/PEEP-FiO₂ table. The primary outcome is V/Q matching percentage assessed by EIT at 18 hours of prone positioning (T2) and 6 hours after supine repositioning (T3). Secondary outcomes include respiratory mechanics, EIT-derived parameters (regional ventilation distribution, global inhomogeneity index, center of ventilation), oxygenation indices, echocardiographic measures of cardiac function, and clinical outcomes (28-day mortality, ventilator-free days, ICU length of stay, etc.).
Conclusion: This study will provide physiological evidence for early EIT-guided PEEP titration in patients with moderate-to-severe ARDS undergoing prone positioning, and will lay the foundation for future large-scale clinical trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PEEP will be titrated using EIT monitoring at 4 hours after prone positioning initiation (T1). The optimal PEEP will be determined at the intersection of the cumulative collapse and overdistension curves, or at the lowest global inhomogeneity index if the intersection occurs between two PEEP levels.
Other: EIT-Guided PEEP Titration Group
PEEP will be set according to the ARDSNet/PEEP-FiO₂ table at 4 hours after prone positioning initiation (T1).
Other: ARDSNet/PEEP-FiO₂ Table
PEEP titration is performed during mechanical ventilation to optimize respiratory mechanics and ventilation-perfusion matching in patients with ARDS.
PEEP will be set according to the ARDSNet/PEEP-FiO₂ table at 4 hours after prone positioning initiation (T1).
Ventilation-Perfusion (V/Q) Matching Percentage
V/Q matching percentage assessed by electrical impedance tomography (EIT) using the EIT Evaluation Tool (SDMI) V2.7.1. V/Q matching reflects the efficiency of pulmonary gas exchange and is calculated from regional ventilation and perfusion distribution maps.
Time frame: At 18 hours of prone positioning (T2) and at 6 hours after supine repositioning (T3)
Respiratory System Compliance
Respiratory system compliance (Crs) calculated as tidal volume divided by driving pressure (plateau pressure minus PEEP), measured under volume-controlled ventilation.
Time frame: Baseline, T2 (18h prone), and T3 (6h post-supine)
Driving Pressure
Driving pressure (DP) calculated as plateau pressure (Pplat) minus PEEP, measured under volume-controlled ventilation.
Time frame: At baseline (T0), at 18 hours of prone positioning (T2), and at 6 hours after supine repositioning (T3)
EIT-Derived Regional Ventilation Distribution
Regional ventilation distribution assessed by EIT, expressed as percentage of tidal impedance variation in four regions of interest (ROIs): ventral (ROI 1), mid-ventral (ROI 2), mid-dorsal (ROI 3), and dorsal (ROI 4), each corresponding to 25% of the anteroposterior diameter, Center of Ventilation (CoV), Global Inhomogeneity Index (GI), Shunt, Dead Space.
Time frame: At baseline (T0), at 18 hours of prone positioning (T2), and at 6 hours after supine repositioning (T3)
RVEDA/LVEDA
Right Ventricular End-Diastolic Area to Left Ventricular End-Diastolic Area Ratio
Time frame: At baseline (T0) and at 6 hours after supine repositioning (T3)
RVFAC
Right Ventricular Fractional Area Change（%）
Time frame: Baseline and 6h post-supine repositioning (T3)
TAPSE
Tricuspid Annular Plane Systolic Excursion (mm)
Time frame: Baseline and 6h post-supine repositioning (T3)
TRVmax
Maximal Tricuspid Regurgitation Velocity (m/s)
Time frame: Baseline and 6h post-supine repositioning (T3)
LVEF
Left Ventricular Ejection Fraction（%）
Time frame: At baseline (T0) and at 6 hours after supine repositioning (T3)
SV
Stroke Volume（ml）
Time frame: Baseline and 6h post-supine repositioning (T3)
CO
Cardiac Output (L/min)
Time frame: Baseline and 6h post-supine repositioning (T3)
28-Day Mortality
All-cause mortality within 28 days after enrollment.
Time frame: At 28 days after enrollment
Ventilator-Free Days at 28 Days
Number of days alive and free from invasive mechanical ventilation during the first 28 days after enrollment.
Time frame: At 28 days after enrollment
ICU Length of Stay
Total duration of ICU stay (in days) from enrollment to ICU discharge or death.
Time frame: From enrollment through ICU discharge, assessed up to 28 days
Incidence of ECMO Use
Proportion of patients requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO) during the ICU stay.
Time frame: During the ICU stay, assessed up to 28 days
Incidence of Tracheostomy
Proportion of patients undergoing tracheostomy during the ICU stay.
Time frame: During the ICU stay, assessed up to 28 days.
Plan to share: No
Start is estimated for Aug 2026; primary completion for May 2027, 8 months later.
Of 264 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 8 months is below that.
Counting every sponsor, half of 271 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →